Leuko's device, developed by MIT researchers, monitors cancer patients' health during chemotherapy without blood tests, using light and AI to detect low white blood cell counts and potential infections.

US-based firm Leuko, founded by MIT researchers, has developed a device that allows doctors to monitor cancer patients' health during chemotherapy without the need for blood tests. The device uses light to analyze the top of the fingernail and artificial intelligence to detect when white blood cell counts are dangerously low, helping doctors spot life-threatening infections in cancer patients remotely.

June 16, 2024
4 Articles

Further Reading